Euclises Pharmaceuticals is a drug discovery and development company developing third-generation COX-2 inhibitors for cancer treatment
Euclises Pharmaceuticals is a drug discovery and development company developing third-generation COX-2 inhibitors for cancer treatment. Its lead candidate, ECP-1014, is designed to suppress COX-2-driven PGE-2 production and improve tumor immune control, including in combination with checkpoint inhibitors and other cancer therapies.